Zecotek Awarded Singapore Economic Development Board’s Research Incentive Scheme for Companies Grant.
Vancouver, July 23, 2007 – Zecotek Medical Systems Inc. (TSX-V: ZMS; Frankfurt: W1I.F) today announced, through its wholly owned subsidiary Zecotek Medical Systems Singapore Pte Ltd, that it has received grant approval for the Singapore Economic Development Board’s (EDB) Research Incentive Scheme for Companies program. Under the agreement the terms of the grant details remain confidential. (Details of EDB’s support programs can be found on EDB’s website www.edb.gov.sg).
Zecotek has established Singapore’s first bio-photonics research and development facility in the prestigious Science Park II to develop and bring to market bio-photonic technologies. The new labs will complete the development and production of Zecotek’s key technologies in areas of medical imaging, medical lasers and 3D display. Current projects include: final stage development of its proprietary MAPD solid-state photo detector, production prototyping of its 3D display; commercial production of its proprietary RFO high-performance vanadate crystals; and development of several new types of solid-state and fiber lasers.
“Our move to Singapore last year was with the full encouragement and invitation of EDB in an effort to reduce Zecotek’s overall operating costs and to leverage Singapore’s research & development efficiencies and its strong, high-technology manufacturing base,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Medical Systems. “The EDB team has demonstrated their continuing and enthusiastic support to our efforts. We look forward to continuing to work with the EDB team as we transition from a purely research and development organization and bring to market several new generation technologies.”
Mr. Kenneth Tan, Executive Director, New Businesses Group of EDB said, “We are delighted with Zecotek’s decision to locate key operations in Singapore and the speed in which they have established their new facilities. Their impressive range of photonics technologies and products are a welcome addition to Singapore’s growing industrial capabilities in photonics and medical imaging.’
– 30 –
Zecotek Medical Systems (TSX-V: ZMS; Frankfurt: W1I.F) is a bio-photonics technology company developing high-performance crystals, photo detectors, medical lasers, optical imaging and 3D display technologies for commercial applications in the medical diagnostics and high-tech industry. Founded in 2003, the company has three distinct operating divisions: medical imaging, medical lasers and 3D display and labs located in Canada, Singapore and Russia. Zecotek commercializes its novel, patented and patent-pending bio-photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders.
This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
For additional information on Zecotek Medical Systems and our technologies please see our website at Zecotek Photonics.
For additional information please contact:
CFO; VP Corporate Development
T: (604) 827-5203
Caliber Capital Partners
T: (778) 327-6678
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at Zecotek Photonics.